AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
Food and Drug Administration has approved Axsome Therapeutics' drug to treat agitation in patients with Alzheimer's ...
The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...
The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
A blood test can now detect Alzheimer’s disease early, and a Canton neurologist is among the first in the country using it.
Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...
Researchers at Washington University School of Medicine in St. Louis analyzed how long 282 Alzheimer’s patients were able to continue living independently after taking two specific treatments: ...
IFLScience on MSN
Blocking a single protein in Alzheimer’s disease could boost the brain’s cleanup crew, slowing memory loss
Inhibiting an enzyme in the brain could unlock a novel way of slowing Alzheimer’s disease, a new study suggests. With ...
Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...
In "Beyond Diagnosis: Alzheimer's Disease," Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell discuss how to communicate effectively with patients and families ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results